Community-Based Measures for RSV Immunization

Overseen By RSV Uptake Study Coordinator

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of California, San Francisco

Disqualifiers: Nursing home resident, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

750 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to increase RSV (respiratory syncytial virus) vaccine use among Latinos through community health workers and text messages. It encourages older adults to get vaccinated and motivates younger adults to discuss the vaccine with older family and friends. Participants may receive reminders or counseling, with various approaches tested to determine the most effective. The trial seeks Latino adults: those over 50 who haven't received the RSV vaccine and those aged 18–49 who regularly communicate with older family members. The study focuses on individuals living or working in San Francisco or Daly City.

As an unphased trial, this study provides a unique opportunity to contribute to community health by exploring effective methods to increase vaccine uptake.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that these community-based measures are safe for increasing RSV vaccine use among Latino adults?

Research has shown that RSV vaccines are generally safe for older adults. Studies have found these vaccines to be well-tolerated and approved for individuals aged 60 and older. Large clinical trials demonstrated that the vaccines are 82.4% to 85.7% effective in preventing serious lung infections caused by RSV. Common side effects are mild, including pain at the injection site, tiredness, and headache, while serious side effects are rare. This study does not test the vaccine itself but explores ways to encourage more people to get vaccinated. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about these community-based measures for RSV immunization because they focus on increasing vaccine uptake among Latino adults, a group that often faces barriers to healthcare access. Unlike standard vaccine campaigns that rely heavily on clinic-based advertising, this approach uses community health worker (CHW) text message reminders and personalized counseling to engage and motivate individuals directly. By leveraging trusted community figures and personalized communication, this strategy aims to improve vaccination rates more effectively than traditional methods.

What evidence suggests that this trial's community-based measures could be effective for increasing RSV vaccine use among Latino adults?

Research has shown that RSV vaccines effectively prevent illness. For example, the ABRYSVO vaccine is 62.1% effective, and the AREXVY vaccine is 71.7% effective in preventing RSV-related respiratory illness. In this trial, participants will join different treatment arms using community-based approaches to increase vaccination rates among Latino adults. One arm involves community health workers (CHWs) sending text message reminders only, while another includes both text message reminders and counseling from CHWs. These strategies aim to encourage more people to get vaccinated and discuss the vaccine with their family and friends. ^{1 4 6 7 8}

Who Is on the Research Team?

Carina Marquez, MD

Principal Investigator

University of California, San Francisco

Are You a Good Fit for This Trial?

This trial is for Latino adults who are interested in increasing RSV vaccine use within their community. It's divided into two parts: one focuses on older adults getting vaccinated (Motivate phase), and the other encourages younger adults to talk about vaccination with older relatives (Activate phase).

Inclusion Criteria

Self-identify as Latino/a/x and/or indigenous groups from Latin America

Has a cell phone

Lives or works in San Francisco or Daly City

Exclusion Criteria

Intent to move outside of San Francisco or Daly City in the next year

Nursing home resident

Household member participating in Aim 1 or 2

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Motivate

Randomization of 400 Latino older adults to community health worker counseling and text message nudges vs. CHW delivered RSV vaccine vs. text-message nudges alone

8 weeks

Multiple interactions via text and in-person counseling

Activate

Randomization of 350 Latino adults to CHW 'activation' counseling to encourage discussion of RSV vaccine with older adults in their network plus text-message nudges vs. text-message nudges alone

8 weeks

Multiple interactions via text and in-person counseling

Follow-up

Participants are monitored for RSV vaccine uptake and discussions about RSV vaccination within social networks

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults

Trial Overview The study tests two methods: text message reminders and community health worker (CHW) counseling. There are four groups - some get just texts, others get texts plus CHW counseling, aiming to see which combination is more effective at improving RSV vaccine uptake.

How Is the Trial Designed?

Group I: Motivate Aim: CHW text message reminders and counseling Experimental Treatment 1 Intervention

Group II: Activate Aim: CHW text message reminders and counseling Experimental Treatment 1 Intervention

Group III: Activate Aim: CHW text message reminders only Active Control 1 Intervention

Group IV: Motivate Aim: CHW text message reminders only Active Control 1 Intervention

Who Is Running the Clinical Trial?

University of California, San Francisco

Lead Sponsor

Trials

2,636

Recruited

19,080,000+

Mission Language Vocational School

Collaborator

National Institute on Minority Health and Health Disparities (NIMHD)

Collaborator

Trials

473

Recruited

1,374,000+

Citations

1. clinicaltrials.ucbraid.org clinicaltrials.ucbraid.org/trial/NCT07171164

Community-Based Measures to Increase RSV Vaccine Use ... In collaboration with community-based organizations, this study will focus on increasing RSV vaccine use among Latinos.

2. reporter.nih.gov reporter.nih.gov/search/iWkgKaHSFkCC9pTYdEX36A/project-details/10943906

Project Details In two trials we will determine the effectiveness of community health worker counseling and text-message interventions to (1) increase RSV vaccine uptake among ...

3. clinicaltrials.ucsf.edu clinicaltrials.ucsf.edu/rsv-immunization

UCSF RSV Immunization Clinical Trials for 2025 In collaboration with community-based organizations, this study will focus on increasing RSV vaccine use among Latinos.

4. patlynk.com patlynk.com/trial/NCT07171164

RSV Vaccine Uptake in Latino Older Adults The study focuses on increasing the uptake of the RSV (respiratory syncytial virus) vaccine among Latino older adults. This is achieved by using a community-

5. sciencedirect.com sciencedirect.com/science/article/pii/S2352396425004050

Respiratory syncytial virus (RSV) vaccine effectiveness and ... Clinical trials have demonstrated the efficacy of RSV vaccines (62.1% for ABRYSVO and 71.7% for AREXVY) against RSV-related acute respiratory illness in this ...

6. academic.oup.com academic.oup.com/ofid/article/12/7/ofaf394/8182642

Respiratory Syncytial Virus Risk Assessment in Adults Large clinical trials for these vaccines, performed in adults age ≥60 years, demonstrated 82.4%–85.7% efficacy against lower respiratory tract disease (LRTD) ...

7. jamanetwork.com jamanetwork.com/journals/jamanetworkopen/fullarticle/2832051

Patient- and Community-Level Characteristics Associated ... This cross-sectional study assesses patient- and community-level characteristics associated with respiratory syncytial virus vaccination and ...

8. tandfonline.com tandfonline.com/doi/full/10.1080/14760584.2025.2539892

Public health impact of the adjuvanted RSVPreF3 vaccine ... Our results showed a substantial burden of RSV in Latin America that could be greatly alleviated through adjuvanted RSVPreF3 vaccination of adults ≥60 years.